Therapeutic Plasma Exchange

TPE works by physically removing plasma proteins and other circulating factors from the bloodstream, which is why it has well-established, FDA-recognized medical uses for conditions driven by harmful circulating antibodies or proteins — including certain autoimmune neurological diseases (like Guillain-Barré syndrome and myasthenia gravis crisis), some kidney diseases, and specific blood disorders — where removing the offending antibody or protein directly treats the underlying problem.

Interest in plasma exchange for aging stems partly from a body of research called heterochronic parabiosis, in which the circulatory systems of a young and an old laboratory mouse are surgically joined, sharing blood. These experiments (notably from Irina Conboy's and Thomas Rando's labs at UC Berkeley and Stanford) have shown that young mouse blood can improve some regenerative and tissue-function measures in old mice, and that old mouse blood can impair young mouse tissue function — suggesting that circulating factors change with age in ways that affect tissue health, in both directions.

The leap from that mouse parabiosis research to plasma exchange as a human anti-aging therapy is a substantial one that has not been validated by human trials: parabiosis physically joins two circulatory systems and continuously exchanges blood, which is mechanistically very different from a single or occasional plasma exchange procedure that dilutes and replaces plasma with a generic substitute fluid rather than young donor plasma with matched biological factors. No completed randomized controlled human trial has demonstrated that TPE, as offered at longevity clinics, extends lifespan, reverses a hallmark of aging, or produces a general anti-aging benefit — this remains a hypothesis extrapolated from an interesting but mechanistically distinct animal model.